Project Grant HT94252410050
Award Date
2/1/24
Completion Date
1/31/26
Dollars Obligated
$308K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
The federal Project Grant award of $1,499,912 was granted by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The Bronx Veterans Medical Research Foundation, Inc. (BVMRF). The funding supports a 3-year study on the safety, tolerability, and outcomes of psilocybin in veterans with spinal cord injury. BVMRF, a non-profit medical research organization specializing in veteran-focused healthcare, will conduct this specialized medical research...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $246,000.00 to The Trustees of Princeton University to investigate the brain mechanisms underlying the therapeutic potential of psilocybin. The research aims to: 1) examine the accelerated acquisition of motivated behavior and task performance after psilocybin administration, and 2) identify the cellular and brain-wide substrates driving...
This federal Project Grant award of $249,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is supporting research conducted by the University of Maryland, Baltimore (UMB) to gain insights into multiple sclerosis pathology. The research project will leverage 7-T MRI and multiomics analysis of serologic samples to advance the understanding of this neurological disorder. The award period runs from August 15, 2024 to August 14,...
The National Institute of Mental Health (NIMH) awarded a $679,118 Project Grant (CFDA 93.242 - Mental Health Research Grants) to the University of California, Santa Cruz (UCSC) to study the cellular and circuit mechanisms underlying the long-lasting therapeutic effects of the psychedelic drug psilocybin in the stressed brain. The project aims to determine how psilocybin affects synaptic plasticity, cortical functional networks, and the representation of behavioral variables in the stressed...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,003,539.00 to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. to conduct AI-based screening of ultralarge chemical libraries to identify selective muscarinic receptor antagonists as potential peripheral neuropathy therapeutics. The award period runs from April 1, 2025 through March 31, 2028. The Military Medical...
The University of Maryland, Baltimore (UMB) was awarded a $587,271 Project Grant from the Defense Health Agency, under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), to conduct research on "DUAL INHIBITION OF PARP AND IL-6 AS A NOVEL THERAPEUTIC APPROACH FOR BRCA-MUTATED TRIPLE-NEGATIVE BREAST CANCER." This research project will occur from July 1, 2024 to June 30, 2027. The Military Medical Research and Development program supports a...
This federal Project Grant award of $400,000.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, with a performance period from October 1, 2024 to September 30, 2026. The award supports research by the University of Maryland, Baltimore to develop "drug conjugates of modified LGR4/5/6 ligands for cancer treatment." The university, as the prime awardee, has extensive expertise in biomedical research, clinical trials, and...
The federal Project Grant award of $200,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support research conducted by Northwestern University to elucidate the neural basis of hallucinations in Parkinson's disease. The award, effective July 1, 2025 through June 30, 2027, will enable Northwestern University's researchers to investigate this critical medical challenge and develop innovative solutions to transform healthcare for military...
This Project Grant award from the National Center for Complementary and Integrative Health (NCCIH), under the federal Research and Training in Complementary and Integrative Health program (CFDA 93.213), will fund a feasibility clinical trial to develop and evaluate a Psilocybin-Assisted Cognitive Behavioral Therapy (PA-CBT) protocol for treating major depressive disorder. The $236,250 award, granted on December 17, 2024, supports a 3-year study to refine and optimize the PA-CBT approach, and...
The University of Arizona was awarded a $1,791,407 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to conduct research on "Targeting Drug Resistance in the Bone Microenvironment Using a Novel PIM-PROTAC". The 3-year grant, running from March 1, 2025 to February 29, 2028, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The funding will...